|
|
|
|
We did not find consistent evidence to show that HBOT improves clinical outcomes when applied during the acute presentation of ischemic stroke. Few of the included cases were truly acute (within 6 hours of symptom onset). Whereas evidence from the 6 randomized controlled trials is insufficient to provide clear guidelines for practice, the possibility of clinical benefit has not been excluded. Further research is required to better-define the role of HBOT in this condition. |
|